A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole (Femara®) as preoperative therapy of primary breast cancer in postmenopausal women
WO17299
Biomarker Program
A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole (Femara®) as preoperative therapy of primary breast cancer in postmenopausal women
Phase II
Status
Finished
Tumour subtype:
HR+
Scenario
Neoadyuvante
Sites
